Table 5.

Development of Steroid Comorbidities (Predictors of Development of Steroid-related Comorbidity after Diagnosis with Sarcoidosis)

	Univariate [OR (95% CI)]	Multivariate, LASSO [OR (95% CI)] (n = 988)
Income
≥$85,000	Ref	Ref
$35,000–84,999	1.7 (1.4–2.1)	1.5 (1.1–2.1)
<$35,000	2.2 (1.7–2.8)	1.3 (0.9–2.0)
Age	1.04 (1.03–1.04)	1.04 (1.02–1.05)
Sex, M	0.8 (0.7–0.97)	0.7 (0.5–0.95)
Race
White	Ref	Ref
African American	2.0 (1.6–2.5)	2.0 (1.4–3.0)
Other	1.7 (1.2–2.3)	1.9 (1.1–3.3)
Insurance type
Private	Ref	Ref
Government	2.1 (1.7–2.6)	1.5 (1.1–2.2)
No coverage	1.0 (0.6–1.6)	0.8 (0.4–1.9)
Household size	0.9 (0.9–0.996)	—
Patient education		—
>College	Ref
College	1.2 (0.96–1.6)
Post-HS education	1.5 (1.1–1.9)
HS	1.6 (1.2–2.1)
Pulmonary involvement	1.9 (1.5–2.4)	2.1 (1.4–3.2)
Neurologic involvement	2.4 (1.9–3.1)	2.4 (1.6–3.5)
Cardiac involvement	1.7 (1.4–2.2)	1.4 (0.96–1.9)
Ocular involvement	2.4 (1.9–2.9)	1.6 (1.2–2.2)
Skin involvement	1.8 (1.5–2.2)	—
Duration of symptoms	1.07 (1.06–1.08)	1.04 (1.02–1.05)
Medication history		—
Never	Ref	Ref
Past	3.4 (2.5–4.7)	2.1 (1.3–3.5)
Current	3.0 (2.3–4.0)	2.6 (1.6–4.1)

For definition of abbreviations, see Table 4.

Variables that were significant (P < 0.05) in multivariate analysis are in boldface.